Kiora reports 2023 net loss $12.5M; cash >$30M post partnership and placement

KIORA PHARMACEUTICALS INC

Net loss $12.5M in 2023 vs $13.6M in 2022; R&D expense $4.0M, G&A $4.7M.
Cash and equivalents $2.5M at year-end 2023; $16M upfront from TOI partnership and $13.8M private placement net proceeds in Feb 2024 raised cash >$30M.
Company expects existing cash to fund operations through 2026.
KIO-301 Phase 2 trial in retinitis pigmentosa expected to start Q4 2024; KIO-104 Phase 2 planning underway.
Partnership with Théa Open Innovation grants exclusive rights to KIO-301 outside Asia; potential milestones up to $285M plus tiered royalties.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KIORA PHARMACEUTICALS INC reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

Kiora Pharmaceuticals, Inc. (the "Company") issued a press release announcing financial results for the year ended December 31, 2023 and an update on clinical development progress.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001372514-24-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.